Summary
The Improved Prostate Cancer Diagnosis–Combination of Magnetic Resonance Imaging and Biomarkers trial [IMPROD; NCT01864135] was designed to assess the accuracy of a biparametric magnetic resonance imaging approach and targeted biopsy for patients suspected of having prostate cancer based on digital rectal examination or an elevated prostate-specific antigen value > 2.5 ng/mL. This article discusses the preliminary results.
- magnetic resonance imaging
- reproductive cancers
- radiology clinical trials
- © 2015 MD Conference Express®
Tools
Table of contents
Cited By...
- No citing articles found.